Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb Company has announced that the FDA has approved Orencia for reducing signs and symptoms in pediatric patients six years and older with moderately to severely active polyarticular juvenile idiopathic arthritis.
Subscribe to our email newsletter
This new indication for Orencia provides significant evidence of its durable efficacy and long-term safety in pediatric patients, including those initiating biologic therapy for the first time. The safety and efficacy of Orencia in juvenile idiopathic arthritis (JIA) were assessed in a three-part study through one year.
Elliott Sigal, executive vice president, chief scientific officer and president, R&D, Bristol-Myers Squibb, said: “Juvenile idiopathic arthritis is the most prevalent form of arthritis in children. This new indication for Orencia offers another treatment option to help improve signs and symptoms of this serious disease in pediatric and adolescent patients.”